Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.

Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Füner L, Härdtner C, Stachon P, Wolf D, Hilgendorf I, Mullick A, Bode C, Zirlik A, Goldberg IJ, Willecke F.

Sci Rep. 2019 Nov 29;9(1):17937. doi: 10.1038/s41598-019-54224-9.

2.

Different blood pressure responses in hypertensive rats following chemerin mRNA inhibition in dietary high fat compared to dietary high-salt conditions.

Ferland DJ, Flood ED, Garver H, Yeh ST, Riney S, Mullick AE, Fink GD, Watts SW.

Physiol Genomics. 2019 Nov 1;51(11):553-561. doi: 10.1152/physiolgenomics.00050.2019. Epub 2019 Oct 7.

PMID:
31588871
3.

Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor.

Bashore AC, Liu M, Key CC, Boudyguina E, Wang X, Carroll CM, Sawyer JK, Mullick AE, Lee RG, Macauley SL, Parks JS.

Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1747-1761. doi: 10.1161/ATVBAHA.119.312382. Epub 2019 Jun 6.

PMID:
31167565
4.

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.

Prakash TP, Mullick AE, Lee RG, Yu J, Yeh ST, Low A, Chappell AE, Østergaard ME, Murray S, Gaus HJ, Swayze EE, Seth PP.

Nucleic Acids Res. 2019 Jul 9;47(12):6029-6044. doi: 10.1093/nar/gkz354.

5.

Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates.

Østergaard ME, Jackson M, Low A, E Chappell A, G Lee R, Peralta RQ, Yu J, Kinberger GA, Dan A, Carty R, Tanowitz M, Anderson P, Kim TW, Fradkin L, Mullick AE, Murray S, Rigo F, Prakash TP, Bennett CF, Swayze EE, Gaus HJ, Seth PP.

Nucleic Acids Res. 2019 Jul 9;47(12):6045-6058. doi: 10.1093/nar/gkz360.

6.

Reducing recombinant protein expression during CHO pool selection enhances frequency of high-producing cells.

Poulain A, Mullick A, Massie B, Durocher Y.

J Biotechnol. 2019 Apr 20;296:32-41. doi: 10.1016/j.jbiotec.2019.03.009. Epub 2019 Mar 15.

PMID:
30885656
7.

Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report.

Ye F, Wang Y, Wu C, Howatt DA, Wu CH, Balakrishnan A, Mullick AE, Graham MJ, Danser AHJ, Wang J, Daugherty A, Lu HS.

Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):150-155. doi: 10.1161/ATVBAHA.118.311817.

PMID:
30567480
8.

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Wu CH, Wang Y, Ma M, Mullick AE, Crooke RM, Graham MJ, Daugherty A, Lu HS.

Biosci Rep. 2019 Jan 11;39(1). pii: BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Review.

9.

Effect of Transcutaneous Electrical Nerve Stimulation on Spasticity in Adults With Stroke: A Systematic Review and Meta-analysis.

Mahmood A, Veluswamy SK, Hombali A, Mullick A, N M, Solomon JM.

Arch Phys Med Rehabil. 2019 Apr;100(4):751-768. doi: 10.1016/j.apmr.2018.10.016. Epub 2018 Nov 16. Review.

PMID:
30452892
10.

Facilitators and barriers to using neurological outcome measures in developed and developing countries.

Demers M, Blanchette AK, Mullick AA, Shah A, Woo K, Solomon J, Levin MF.

Physiother Res Int. 2019 Jan;24(1):e1756. doi: 10.1002/pri.1756. Epub 2018 Nov 7.

PMID:
30403320
11.

Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition.

Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, Di Prospero NA, Eckel RH, Goldberg IJ.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2207-2216. doi: 10.1161/ATVBAHA.118.311339.

12.

Ultrasound assisted synthesis of Mg-Mn-Zr impregnated activated carbon for effective fluoride adsorption from water.

Mullick A, Neogi S.

Ultrason Sonochem. 2019 Jan;50:126-137. doi: 10.1016/j.ultsonch.2018.09.010. Epub 2018 Sep 5.

PMID:
30245202
13.

Endothelial cell CD36 optimizes tissue fatty acid uptake.

Son NH, Basu D, Samovski D, Pietka TA, Peche VS, Willecke F, Fang X, Yu SQ, Scerbo D, Chang HR, Sun F, Bagdasarov S, Drosatos K, Yeh ST, Mullick AE, Shoghi KI, Gumaste N, Kim K, Huggins LA, Lhakhang T, Abumrad NA, Goldberg IJ.

J Clin Invest. 2018 Oct 1;128(10):4329-4342. doi: 10.1172/JCI99315. Epub 2018 Jul 26.

14.

The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Watts SW, Darios ES, Mullick AE, Garver H, Saunders TL, Hughes ED, Filipiak WE, Zeidler MG, McMullen N, Sinal CJ, Kumar RK, Ferland DJ, Fink GD.

FASEB J. 2018 Jun 15:fj201800479. doi: 10.1096/fj.201800479. [Epub ahead of print]

15.

Acoustic cavitation induced synthesis of zirconium impregnated activated carbon for effective fluoride scavenging from water by adsorption.

Mullick A, Neogi S.

Ultrason Sonochem. 2018 Jul;45:65-77. doi: 10.1016/j.ultsonch.2018.03.002. Epub 2018 Mar 5.

PMID:
29705326
16.

Reduced Kinematic Redundancy and Motor Equivalence During Whole-Body Reaching in Individuals With Chronic Stroke.

Tomita Y, Mullick AA, Levin MF.

Neurorehabil Neural Repair. 2018 Feb;32(2):175-186. doi: 10.1177/1545968318760725.

PMID:
29554848
17.

Whole-Body but Not Hepatic Knockdown of Chemerin by Antisense Oligonucleotide Decreases Blood Pressure in Rats.

Ferland DJ, Seitz B, Darios ES, Thompson JM, Yeh ST, Mullick AE, Watts SW.

J Pharmacol Exp Ther. 2018 May;365(2):212-218. doi: 10.1124/jpet.117.245456. Epub 2018 Feb 21.

18.

Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor.

Basu D, Hu Y, Huggins LA, Mullick AE, Graham MJ, Wietecha T, Barnhart S, Mogul A, Pfeiffer K, Zirlik A, Fisher EA, Bornfeldt KE, Willecke F, Goldberg IJ.

Circ Res. 2018 Feb 16;122(4):560-567. doi: 10.1161/CIRCRESAHA.117.311361. Epub 2018 Jan 10.

19.

(Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis.

Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, Daugherty A, Li F, Wang M, Su F, Tao W, Sun J, Zelcer N, Mullick AE, Danser AHJ, Jiang Y, He Y, Ruan X, Lu X.

Circ Res. 2018 Mar 2;122(5):730-741. doi: 10.1161/CIRCRESAHA.117.312422. Epub 2018 Jan 4.

20.

Referent control of the orientation of posture and movement in the gravitational field.

Mullick AA, Turpin NA, Hsu SC, Subramanian SK, Feldman AG, Levin MF.

Exp Brain Res. 2018 Feb;236(2):381-398. doi: 10.1007/s00221-017-5133-y. Epub 2017 Nov 21.

PMID:
29164285
21.

Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.

Fitzgibbon WR, Dang Y, Bunni MA, Baicu CF, Zile MR, Mullick AE, Saigusa T.

Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F210-F218. doi: 10.1152/ajprenal.00389.2017. Epub 2017 Oct 11.

22.

Assisted Design of Antibody and Protein Therapeutics (ADAPT).

Vivcharuk V, Baardsnes J, Deprez C, Sulea T, Jaramillo M, Corbeil CR, Mullick A, Magoon J, Marcil A, Durocher Y, O'Connor-McCourt MD, Purisima EO.

PLoS One. 2017 Jul 27;12(7):e0181490. doi: 10.1371/journal.pone.0181490. eCollection 2017.

23.

Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.

Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM.

Hypertension. 2017 Sep;70(3):566-576. doi: 10.1161/HYPERTENSIONAHA.117.09755. Epub 2017 Jul 17.

PMID:
28716988
24.

Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch.

Poulain A, Perret S, Malenfant F, Mullick A, Massie B, Durocher Y.

J Biotechnol. 2017 Aug 10;255:16-27. doi: 10.1016/j.jbiotec.2017.06.009. Epub 2017 Jun 15.

PMID:
28625678
25.

Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Ferrario CM, Mullick AE.

Pharmacol Res. 2017 Nov;125(Pt A):57-71. doi: 10.1016/j.phrs.2017.05.020. Epub 2017 May 29. Review.

26.

Current Practices of Physical and Occupational Therapists Regarding Spasticity Assessment and Treatment.

Blanchette AK, Demers M, Woo K, Shah A, Solomon JM, Mullick AA, Levin MF.

Physiother Can. 2017;69(4):303-312. doi: 10.3138/ptc.2016-54.

27.

Upper Limb Obstacle Avoidance Behavior in Individuals With Stroke.

Baniña MC, Mullick AA, McFadyen BJ, Levin MF.

Neurorehabil Neural Repair. 2017 Feb;31(2):133-146. doi: 10.1177/1545968316662527. Epub 2016 Aug 20.

PMID:
27542986
28.

Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.

Lu H, Howatt DA, Balakrishnan A, Graham MJ, Mullick AE, Daugherty A.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1753-7. doi: 10.1161/ATVBAHA.116.307613. Epub 2016 Jul 28.

29.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD.

J Clin Invest. 2016 Aug 1;126(8):2855-66. doi: 10.1172/JCI86610. Epub 2016 Jul 11.

30.

Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.

Souza AC, Bocharov AV, Baranova IN, Vishnyakova TG, Huang YG, Wilkins KJ, Hu X, Street JM, Alvarez-Prats A, Mullick AE, Patterson AP, Remaley AT, Eggerman TL, Yuen PS, Star RA.

Kidney Int. 2016 Apr;89(4):809-22. doi: 10.1016/j.kint.2015.12.043.

31.

Angiotensinogen Exerts Effects Independent of Angiotensin II.

Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):256-65. doi: 10.1161/ATVBAHA.115.306740. Epub 2015 Dec 17.

32.

Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.

Landge S, Mullick AB, Nagalapur K, Neres J, Subbulakshmi V, Murugan K, Ghosh A, Sadler C, Fellows MD, Humnabadkar V, Mahadevaswamy J, Vachaspati P, Sharma S, Kaur P, Mallya M, Rudrapatna S, Awasthy D, Sambandamurthy VK, Pojer F, Cole ST, Balganesh TS, Ugarkar BG, Balasubramanian V, Bandodkar BS, Panda M, Ramachandran V.

Bioorg Med Chem. 2015 Dec 15;23(24):7694-710. doi: 10.1016/j.bmc.2015.11.017. Epub 2015 Nov 18.

PMID:
26643218
33.

CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.

Donner AJ, Yeh ST, Hung G, Graham MJ, Crooke RM, Mullick AE.

Mol Ther Nucleic Acids. 2015 Dec 1;4:e265. doi: 10.1038/mtna.2015.40.

34.

Tonic Stretch Reflex Threshold as a Measure of Ankle Plantar-Flexor Spasticity After Stroke.

Blanchette AK, Mullick AA, Moïn-Darbari K, Levin MF.

Phys Ther. 2016 May;96(5):687-95. doi: 10.2522/ptj.20140243. Epub 2015 Oct 8.

PMID:
26450971
35.

Emerging evidence of the association between cognitive deficits and arm motor recovery after stroke: A meta-analysis.

Mullick AA, Subramanian SK, Levin MF.

Restor Neurol Neurosci. 2015;33(3):389-403. doi: 10.3233/RNN-150510.

36.

Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.

Saigusa T, Dang Y, Mullick AE, Yeh ST, Zile MR, Baicu CF, Bell PD.

FASEB J. 2016 Jan;30(1):370-9. doi: 10.1096/fj.15-279299. Epub 2015 Sep 21.

37.

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.

Thompson CM, Petiot E, Mullick A, Aucoin MG, Henry O, Kamen AA.

BMC Biotechnol. 2015 May 16;15:31. doi: 10.1186/s12896-015-0152-x.

38.

Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.

Ravichandran K, Ozkok A, Wang Q, Mullick AE, Edelstein CL.

Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F349-57. doi: 10.1152/ajprenal.00478.2014. Epub 2014 Dec 23.

39.

Genetic control of susceptibility to Candida albicans in SM/J mice.

Radovanovic I, Leung V, Iliescu A, Bongfen SE, Mullick A, Langlais D, Gros P.

J Immunol. 2014 Aug 1;193(3):1290-300. doi: 10.4049/jimmunol.1400783. Epub 2014 Jun 27.

40.

An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.

Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL.

Hum Mol Genet. 2014 Sep 15;23(18):4919-31. doi: 10.1093/hmg/ddu208. Epub 2014 May 8.

41.

An introduction to advance care planning in practice.

Mullick A, Martin J, Sallnow L.

BMJ. 2013 Oct 21;347:f6064. doi: 10.1136/bmj.f6064. Review. No abstract available.

PMID:
24144870
42.

CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation.

Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ.

Nat Immunol. 2013 Aug;14(8):812-20. doi: 10.1038/ni.2639. Epub 2013 Jun 30.

43.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM.

J Lipid Res. 2013 Oct;54(10):2647-57. doi: 10.1194/jlr.M036509. Epub 2013 Jun 25.

44.

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.

Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM.

Circ Res. 2013 May 24;112(11):1479-90. doi: 10.1161/CIRCRESAHA.111.300367. Epub 2013 Mar 29.

PMID:
23542898
45.

Human cancerous and healthy cell cytotoxicity studies of a chiral μ-dicarbene-digold(I) metallamacrocycle.

Mullick AB, Chang YM, Ghiviriga I, Abboud KA, Tan W, Veige AS.

Dalton Trans. 2013 May 28;42(20):7440-6. doi: 10.1039/c3dt32844a.

PMID:
23459659
46.

Inclusive indoor play: an approach to developing inclusive design guidelines.

Mullick A.

Work. 2013;44 Suppl 1:S5-17. doi: 10.3233/WOR-121489.

PMID:
23241690
47.

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM.

J Lipid Res. 2013 Mar;54(3):602-14. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6.

48.

Stretch reflex spatial threshold measure discriminates between spasticity and rigidity.

Mullick AA, Musampa NK, Feldman AG, Levin MF.

Clin Neurophysiol. 2013 Apr;124(4):740-51. doi: 10.1016/j.clinph.2012.10.008. Epub 2012 Nov 10.

PMID:
23146713
49.

Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis.

Kluve-Beckerman B, Hardwick J, Du L, Benson MD, Monia BP, Watt A, Crooke RM, Mullick A.

Amyloid. 2011 Sep;18(3):136-46. doi: 10.3109/13506129.2011.597464. Epub 2011 Aug 10.

PMID:
21830877
50.

A novel role for the fifth component of complement (C5) in cardiac physiology.

Mullick A, Tremblay J, Leon Z, Gros P.

PLoS One. 2011;6(8):e22919. doi: 10.1371/journal.pone.0022919. Epub 2011 Aug 1.

Supplemental Content

Loading ...
Support Center